Eagle Pharmaceuticals Inc

EGRX

NASDAQ. Currency in USD

26.99 -0.14 ( -0.52% )

Real time prices: September 23

Market Cap.
358.55M
Beta (5Y monthly)
0.66
Price/Earnings
4.34
EPS (TTM)
7.01
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
150,867
1y Target Est.
50.50
Day's Range
26.58
-
27.27
52 Week's Range
26.21
-
58.25

Historical Summary

Performance
EPS growth
Share Buybacks

About Eagle Pharmaceuticals Inc

Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Website
https://www.eagleus.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
12.91M
Employees
102
Address
50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Latest news

New Strong Sell Stocks for September 9th
New Strong Sell Stocks for September 9th

EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List...
By Zacks Investment Research - 2 weeks ago

New Strong Sell Stocks for September 1st
New Strong Sell Stocks for September 1st

CCCS, BJRI and EGRX have been added to the Zacks Rank #5 (Strong Sell) List...
By Zacks Investment Research - 3 weeks ago

Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”...
By GlobeNewswire Inc. - 3 weeks ago

Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?
Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?

Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II...
By Zacks Investment Research - 4 weeks ago

Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation
Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation

WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”...
By GlobeNewswire Inc. - 5 weeks ago

Eli Lilly's (LLY) Potential New Products Key to Growth
Eli Lilly's (LLY) Potential New Products Key to Growth

Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type...
By Zacks Investment Research - 5 weeks ago

Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript
Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript

EGRX earnings call for the period ending June 30, 2022.
By The Motley Fool - 6 weeks ago

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the...
By Zacks Investment Research - 6 weeks ago